Segment Reporting (Details) $ in Thousands |
3 Months Ended | 6 Months Ended | ||||
|---|---|---|---|---|---|---|
|
Jun. 30, 2025
USD ($)
|
Mar. 31, 2025
USD ($)
|
Jun. 30, 2024
USD ($)
|
Mar. 31, 2024
USD ($)
|
Jun. 30, 2025
USD ($)
segment
|
Jun. 30, 2024
USD ($)
|
|
| Segment Reporting | ||||||
| Number of operating segments | segment | 1 | |||||
| External R&D expense | $ 62,401 | $ 42,373 | $ 111,079 | $ 85,466 | ||
| Employee related equity-based compensation expense | 37,846 | 17,476 | ||||
| Depreciation and amortization expense | 810 | 1,096 | ||||
| Other expense, net | (127) | (14) | (171) | (36) | ||
| Net loss | 110,031 | $ 74,723 | 58,508 | $ 56,853 | 184,754 | 115,361 |
| Operating segment | ||||||
| Segment Reporting | ||||||
| Employee related expense | 32,484 | 16,120 | 55,422 | 32,200 | ||
| External expense - G&A | 14,952 | 6,127 | 23,895 | 11,128 | ||
| Other segment related expense | 6,273 | 4,882 | $ 11,531 | 9,739 | ||
| Description-Other segment related expense | Consists of other segment expenses related to supplies, corporate and facilities expenses. | |||||
| Employee related equity-based compensation expense | 24,433 | 9,312 | $ 37,846 | 17,476 | ||
| Depreciation and amortization expense | 417 | 500 | 810 | 1,096 | ||
| Other expense, net | (2,078) | (990) | (4,445) | (2,556) | ||
| Net loss | 110,031 | 58,508 | 184,754 | 115,361 | ||
| Operating segment | Apitegromab | ||||||
| Segment Reporting | ||||||
| External R&D expense | 27,956 | 17,082 | 47,257 | 35,330 | ||
| Operating segment | SRK-181 | ||||||
| Segment Reporting | ||||||
| External R&D expense | 792 | 3,258 | 1,902 | 6,005 | ||
| Operating segment | SRK-439 | ||||||
| Segment Reporting | ||||||
| External R&D expense | 2,575 | 1,550 | 6,854 | 3,534 | ||
| Operating segment | Early research and other | ||||||
| Segment Reporting | ||||||
| External R&D expense | $ 2,227 | $ 667 | $ 3,682 | $ 1,409 | ||
| X | ||||||||||
- Definition The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Definition The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of general and administrative expense classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of income (expense) related to nonoperating activities, classified as other. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- Definition Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss). Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Description of composition of other segment item not separately disclosed. Reference 1: http://www.xbrl.org/2003/role/exampleRef
|
| X | ||||||||||
- Definition Amount of noncash expense for share-based payment arrangement. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|